Read More

‘Highly Compelling’ Eye Drug Data Has Wall Street Stampeding To Buy This ‘Large Cap Growth Story.’ Even After $15B In Market Cap Was Added

Morgan Stanley upgraded Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) to Overweight from Equal Weight with a price target of $851, up from $625.  The analyst…

REGN

Read More

‘Nobody Knows’: The Mystery Of Where Your Personal Facebook Data Goes

Earlier this year in March, two senior Facebook engineers who have a combined 20 years of experience between them found themselves perplexed when asked about the company’s mishandeling of private user information stemming from the ongoing Cambridge Analytica lawsuit, according to a new report. 

META